Xian Li

US Patent:

20210380683, Dec 9, 2021

Filed:

Apr 12, 2019

Appl. No.:

17/046843

Inventors:

- Houston TX, US
Xian Chang LI - Houston TX, US

International Classification:

C07K 16/28
A61K 35/17
A61P 37/06

Abstract:

Disclosed are methods and compositions for inhibiting IRF4 in T-cells, thereby improving transplant outcomes or treating an autoimmune disease such as a myelination disorder. Thus, disclosed are methods to improve a transplant outcome in a recipient of a transplant comprising inhibiting IRF4 in T-cells of the recipient, thereby improving the transplant outcome. In some embodiments, IRF4 can be inhibited by administering an IRF4 inhibitor (e.g., trametinib or anti-IRF4 siRNA), and/or by adoptive transfer of T-cells having IRF4 inhibition. In some embodiments, the T-cells are CD4+ Tcells, and the infiltration thereof into a transplant can be reduced. Also disclosed are methods of treating a subject with a myelination disorder (e.g., multiple sclerosis or encephalomyelitis) comprising inhibiting IRF4.

US Patent:

20200405763, Dec 31, 2020

Filed:

Feb 27, 2019

Appl. No.:

16/975933

Inventors:

- Houston TX, US
Xian Chang LI - Houston TX, US

International Classification:

A61K 35/17
C12N 15/86
C12N 5/0783
C07K 14/47
A61K 45/06
A61K 39/395
C07K 16/28
A61K 38/20
A61P 35/00

Abstract:

Methods to treat cancer in a subject comprising administering to the subject a therapeutically effective amount of T-cells of the subject having increased IRF4 polypeptide expression compared to a control are disclosed. Also disclosed are methods of increasing tumor reactivity of a T-cell by increasing IRF4 polypeptide expression, and methods to predict the likelihood that a subject having cancer will respond therapeutically to administered T-cells having increased IRF4 polypeptide expression. Also disclosed are compositions comprising a T-cell and a viral vector encoding an IRF4 polypeptide. The compositions are methods are useful for treating numerous cancers in which higher level expression of IRF4 in T-cells would be beneficial. In some embodiments, activated tumor specific T-cells having increased IRF4 expression have greater infiltration in tumors and enhanced local immunological responses.

US Patent:

20150031582, Jan 29, 2015

Filed:

Jul 28, 2014

Appl. No.:

14/444863

Inventors:

- Houston TX, US
Zhifeng Ren - Houston TX, US
Xian C. Li - Houston TX, US
Renard L. Thomas - Houston TX, US

Assignee:

UNIVERSITY OF HOUSTON SYSTEM - Houston TX

International Classification:

G01N 33/497
G01N 33/493

US Classification:

506 12, 436141, 436129, 436120, 436130, 436128, 422 8201, 506 39

Abstract:

A method comprising (a) obtaining one or more biological samples from a subject wherein the subject has undergone an organ transplant; (b) determining the amount and type of one or more volatile organic compounds in the biological sample; and (c) correlating the amount of volatile organic compounds to a degree of transplant rejection. A device comprising a plurality of sensors configured to detect a plurality of volatile organic compounds in a biological sample of a subject having undergone an organ transplant.